Test results are denoted by a colour change and could be further analysed by a smartphone app, making it attractive as a point-of-care diagnostic device
A multidisciplinary team of researchers at the National University of Singapore (NUS) has developed a portable, easy-to-use device for quick and accurate screening of diseases. This versatile technology platform called enVision (enzyme-assisted nanocomplexes for visual identification of nucleic acids) can be designed to detect a wide range of diseases – from emerging infectious diseases (e.g. Zika and Ebola) and high-prevalence infections (e.g. hepatitis, dengue, and malaria) to various types of cancers and genetic diseases.
enVision takes between 30 minutes to one hour to detect the presence of diseases, which is two to four times faster than existing infection diagnostics methods. In addition, each test kit costs under S$1 – 100 times lower than the current cost of conducting similar tests.
“The enVision platform is extremely sensitive, accurate, fast, and low-cost. It works at room temperature and does not require heaters or special pumps, making it very portable. With this invention, tests can be done at the point-of-care, for instance in community clinics or hospital wards, so that disease monitoring or treatment can be administered in a timely manner to achieve better health outcomes,” said team leader Assistant Professor Shao Huilin from the Biomedical Institute for Global Health Research and Technology (BIGHEART) and Department of Biomedical Engineering at NUS. Asst Prof Shao is also an investigator with the Institute of Molecular and Cell Biology (IMCB) under the Agency for Science, Technology and Research (A*STAR).
Superior sensitivity and specificity compared to clinical gold standard
The research team used the human papillomavirus (HPV), the key cause of cervical cancer, as a clinical model to validate the performance of enVision. In comparison to clinical gold standard, this novel technology has demonstrated superior sensitivity and specificity.
“enVision is not only able to accurately detect different subtypes of the same disease, it is also able to spot differences within a specific subtype of a given disease to identify previously undetectable infections,” Asst Prof Shao added.
Bringing the lab to the patient
In addition, test results are easily visible – the assay turns from colourless to brown if a disease is present – and could also be further analysed using a smartphone for quantitative assessment of the amount of pathogen present. This makes enVision an ideal solution for personal healthcare and telemedicine.
“Conventional technologies – such as tests that rely on polymerase chain reaction to amplify and detect specific DNA molecules – require bulky and expensive equipment, as well as trained personnel to operate these machines. With enVision, we are essentially bringing the clinical laboratory to the patient. Minimal training is needed to administer the ,test and interpret the results, so more patients can have access to effective, lab-quality diagnostics that will substantially improve the quality of care and treatment,” said Dr Nicholas Ho, a researcher from NUS BIGHEART and A*STAR’s IMCB, and co-first author of the study.
Versatile point-of-care diagnostic device
In this study, Asst Prof Shao and her team developed patented DNA molecular machines that can recognise genetic material of different diseases and perform different functions. These molecular machines form the backbone of the enVision platform.
The novel platform adopts a ‘plug-and-play’ modular design and uses microfluidic technology to reduce the amount of samples and biochemical reagents required as well as to optimise the technology’s sensitivity for visual readouts.
“The enVision platform has three key steps – target recognition, target-independent signal enhancement, and visual detection. It employs a unique set of molecular switches, composed of enzyme-DNA nanostructures, to accurately detect, as well as convert and amplify molecular information into visible signals for disease diagnosis,” explained Dr Lim Geok Soon, a researcher from NUS BIGHEART and A*STAR’s IMCB, and co-first author of the study.
Each test is housed in a tiny plastic chip that is preloaded with a DNA molecular machine that is designed to recognise disease-specific molecules. The chip is then placed in a common signal cartridge that contains another DNA molecular machine responsible for producing visual signals when disease-specific molecules are detected.
Multiple units of the same test chip – to test different patient samples for the same disease – or a collection of test chips to detect different diseases could be mounted onto the common cartridge.
“Having a target-independent signal enhancement step frees up the design possibilities for the recognition element. This allows enVision to be programmed as a biochemical computer with varying signals for different combinations of target pathogens. This can be very useful to monitor populations for multiple diseases like dengue and malaria simultaneously, or testing for highly mutable pathogens like the flu with high sensitivity and specificity,” said Dr Ho.
Asst Prof Shao and her team took about a year and a half to develop the enVision platform. Building on the current work, the research team is developing a sample preparation module – for extraction and treatment of DNA material – to be integrated with the enVision platform to enhance point-of-care application. In addition, the research team foresees that the smartphone app could include more advanced image correction and analysis algorithms to further improve its performance for real-world application.
This research work was published in prestigious scientific journal Nature Communications in August 2018, and featured as an Editors’ Highlight by the journal.
The Latest on: Disease diagnostic tool
via Google News
The Latest on: Disease diagnostic tool
- This D.C. biotech is raising millions — and getting its blood test for heart disease closer to realityon December 10, 2019 at 12:15 pm
Tisha Jepson has an ambitious to-do list: Advance clinical studies of her blood test for heart disease, publish research to get payers to cover it, raise millions to build a lab, earn regulatory ...
- Co-Diagnostics, Inc. Launches Vector Control Mosquito Test for EEE Viruson December 10, 2019 at 4:25 am
EEE is a mosquito-borne disease that kills roughly one-third of those infected and typically leaves ... “Since the launch of our NAM-w test earlier this year, developing a diagnostic tool to identify ...
- South Dakota's new diagnostic lab now open for businesson December 9, 2019 at 10:37 am
The newest tool for fighting animal diseases in South Dakota is now open for business. Over the weekend, the transfer of lab equipment from the state's existing Animal Disease Research & Diagnostic ...
- IPRO Creates Kidney Disease Management Toolson December 9, 2019 at 10:00 am
IPRO's CKD Screening App guides physicians in identifying patient CKD risk, selecting appropriate lab tests for diagnosis and making disease staging determination ... For more information, or to ...
- Point Of Care (POC) Diagnostics Market Share, Size 2017-2025 | Top Leading Countries, Companies,on December 9, 2019 at 5:28 am
diagnostics, are medical devices or tools that helps to diagnose the disease in patient's community, usually outside of clinical labs. The point of care allows earlier diagnostics of disease and to ...
- Infectious Disease Diagnostics Market 2019 Size, Share, Trends, Analysis and Growth Forecast to 2025|MRE Reporton December 5, 2019 at 6:46 pm
Infectious disease medicine is method of distinctive the presence of foreign antigen/organism with the assistance of assorted diagnostic tools. Communicable disease conditions area unit extremely ...
- First investigational drug therapy for liver disease NASH awaiting FDA approvalon December 5, 2019 at 3:34 pm
Given the silent nature of the disease, many patients progress to cirrhosis without being diagnosed. While developing an approved therapy is critical, it also will be important to develop simple ...
- Patent Hints The Apple Watch May One Day Track Parkinson's Diseaseon December 5, 2019 at 2:35 pm
That could be helpful, as Apple notes the current treatment for Parkinson’s disease heavily depends on “how precisely clinicians titrate ... To be trusted with any sort of Parkinson’s diagnostic tool, ...
- 6 Experimental Alzheimer’s Disease Diagnostics Projects Get Funding Booston December 4, 2019 at 8:16 pm
Others are working on an intimately related problem: early detection of the disease and related dementias. On Wednesday the New York-based Alzheimer’s Drug Discovery Foundation (ADDF) named six ...
via Bing News